Cargando…
Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
Several recent prospective cardiovascular clinical trials completed with newly developed drugs for the treatment of type 2 diabetes mellitus have been published. Caution must be used when interpreting these studies.[Image: see text]
Autores principales: | Kurose, Takeshi, Hamamoto, Yoshiyuki, Seino, Yutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583954/ https://www.ncbi.nlm.nih.gov/pubmed/28130883 http://dx.doi.org/10.1111/jdi.12635 |
Ejemplares similares
-
Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin
por: Nakatani, Kaori, et al.
Publicado: (2012) -
Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017) -
Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014) -
Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012) -
Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
por: Senmaru, Takafumi, et al.
Publicado: (2012)